Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Poll: Most are satisfied with their health insurance, but a quarter report denials or delays - 2Firefighters rescue two Israelis trapped in vehicles on flooded roads in West Bank
- 3CDC pauses dozens of types of lab testing during evaluation and in wake of downsizing
- 4Italian police hold suspected boss of Naples Mafia's Mazzarella Clan
- 5Most loved Public Dish: Which One Addresses Its Nation Best?
- Flu cases are spiking earlier than usual. What you need to know.
- Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- Asia's Noteworthy Destinations: A Voyager's Aide
- The Best Internet based Retailers for Style and Frill
- There was a bit of toilet trouble on NASA's Artemis 2 mission to the moon
- Picking Your Next SUV: 4 Brands Offering Execution, Solace, and Wellbeing
- Sports Shoes of 2024: Upgrade Execution and Solace
- Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- Witness the elegance of the cosmic butterfly in a remarkable telescope photo
